<DOC>
	<DOCNO>NCT02614820</DOCNO>
	<brief_summary>Background : Duchenne muscular dystrophy ( DMD ) X chromosome recessive hereditary disease mainly characterize progressive muscle weakness atrophy . Glucocorticoid proven effective medicine , side effect limit use . Recent study show vascular density DMD patient ' muscle decrease , muscle ischemic anoxic . Remote ischemic preconditioning ( RIPC ) improve capable resistanting ischemia hypoxia maybe potential therapy DMD patient . Methods : 100 patient ( age 2 6 year ) divide two group ( treatment control group ) randomly . Treatment group receive RIPC stimulus ( inflation blood pressure cuff bilateral thigh 150 mm Hg four 5-minute interval ) control group receive similar stimulus ( inflation blood pressure cuff bilateral thigh 40 mm Hg four 5-minute interval ) . Serum kinase level , Blood level myoglobin , Evaluation motor function ( Four step test ; 6-minute walk test ) MRI low limbs）at 0 day , 3 day , 3months ,6months . Purpose： 1 . To evaluate safety tolerability remote ischemic preconditioning DMD patient 2 . To identify effectiveness remote ischemic preconditioning DMD patient .</brief_summary>
	<brief_title>The Safety , Efficacy Tolerability Remote Ischemic Preconditioning Therapy DMD</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Genetic analysis DMD ; 2 6 year old ; without disease . congenital disease ; upper respiratory infection , gastroenteritis , vaccination , trauma .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Ischemic preconditioning</keyword>
	<keyword>sefety</keyword>
	<keyword>efficacy</keyword>
	<keyword>DMD</keyword>
</DOC>